Cargando…

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti progra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooshkaki, Omid, Derakhshani, Afshin, Safarpour, Hossein, Najafi, Souzan, Vahedi, Parviz, Brunetti, Oronzo, Torabi, Mitra, Lotfinejad, Parisa, Paradiso, Angelo Virgilio, Racanelli, Vito, Silvestris, Nicola, Baradaran, Behzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404077/
https://www.ncbi.nlm.nih.gov/pubmed/32708748
http://dx.doi.org/10.3390/ijms21145034
_version_ 1783567072293289984
author Kooshkaki, Omid
Derakhshani, Afshin
Safarpour, Hossein
Najafi, Souzan
Vahedi, Parviz
Brunetti, Oronzo
Torabi, Mitra
Lotfinejad, Parisa
Paradiso, Angelo Virgilio
Racanelli, Vito
Silvestris, Nicola
Baradaran, Behzad
author_facet Kooshkaki, Omid
Derakhshani, Afshin
Safarpour, Hossein
Najafi, Souzan
Vahedi, Parviz
Brunetti, Oronzo
Torabi, Mitra
Lotfinejad, Parisa
Paradiso, Angelo Virgilio
Racanelli, Vito
Silvestris, Nicola
Baradaran, Behzad
author_sort Kooshkaki, Omid
collection PubMed
description Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti programmed cell death protein-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), and anticytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), which have been approved for treating different types of malignancies. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host–tumor interaction. There are several the US food and drug administration (FDA)-approved ICIs targeting PD-1, including pembrolizumab and nivolumab, as well as those targeting PD-L1, including avelumab, atezolizumab, and durvalumab for melanoma, renal cell cancer, colorectal cancer, head and neck cancer, cervix cancer, urothelial cancer, and lung cancer. Current pre-clinical and clinical studies assessing PD-1/PD-L1 inhibitors in several gynecologic cancers have reported significant antitumor activity. In this review, we investigate pre-clinical and clinical studies that describe the safety and efficacy of anti-PD-1/PD-L1 antibodies, with a particular focus on ongoing clinical trials, analyzing the oncological outcome and adverse effects of ICIs in gynecologic cancers.
format Online
Article
Text
id pubmed-7404077
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74040772020-08-11 The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers Kooshkaki, Omid Derakhshani, Afshin Safarpour, Hossein Najafi, Souzan Vahedi, Parviz Brunetti, Oronzo Torabi, Mitra Lotfinejad, Parisa Paradiso, Angelo Virgilio Racanelli, Vito Silvestris, Nicola Baradaran, Behzad Int J Mol Sci Review Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti programmed cell death protein-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), and anticytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), which have been approved for treating different types of malignancies. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host–tumor interaction. There are several the US food and drug administration (FDA)-approved ICIs targeting PD-1, including pembrolizumab and nivolumab, as well as those targeting PD-L1, including avelumab, atezolizumab, and durvalumab for melanoma, renal cell cancer, colorectal cancer, head and neck cancer, cervix cancer, urothelial cancer, and lung cancer. Current pre-clinical and clinical studies assessing PD-1/PD-L1 inhibitors in several gynecologic cancers have reported significant antitumor activity. In this review, we investigate pre-clinical and clinical studies that describe the safety and efficacy of anti-PD-1/PD-L1 antibodies, with a particular focus on ongoing clinical trials, analyzing the oncological outcome and adverse effects of ICIs in gynecologic cancers. MDPI 2020-07-16 /pmc/articles/PMC7404077/ /pubmed/32708748 http://dx.doi.org/10.3390/ijms21145034 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kooshkaki, Omid
Derakhshani, Afshin
Safarpour, Hossein
Najafi, Souzan
Vahedi, Parviz
Brunetti, Oronzo
Torabi, Mitra
Lotfinejad, Parisa
Paradiso, Angelo Virgilio
Racanelli, Vito
Silvestris, Nicola
Baradaran, Behzad
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
title The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
title_full The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
title_fullStr The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
title_full_unstemmed The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
title_short The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
title_sort latest findings of pd-1/pd-l1 inhibitor application in gynecologic cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404077/
https://www.ncbi.nlm.nih.gov/pubmed/32708748
http://dx.doi.org/10.3390/ijms21145034
work_keys_str_mv AT kooshkakiomid thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT derakhshaniafshin thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT safarpourhossein thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT najafisouzan thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT vahediparviz thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT brunettioronzo thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT torabimitra thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT lotfinejadparisa thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT paradisoangelovirgilio thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT racanellivito thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT silvestrisnicola thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT baradaranbehzad thelatestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT kooshkakiomid latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT derakhshaniafshin latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT safarpourhossein latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT najafisouzan latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT vahediparviz latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT brunettioronzo latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT torabimitra latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT lotfinejadparisa latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT paradisoangelovirgilio latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT racanellivito latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT silvestrisnicola latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers
AT baradaranbehzad latestfindingsofpd1pdl1inhibitorapplicationingynecologiccancers